{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:15:39Z","timestamp":1778163339218,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ero.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T20:21:07Z","timestamp":1749759667000},"page":"63-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Low-dose atovaquone for prophylaxis of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases: an open-label, multicentre, single-arm, phase II trial"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-336X","authenticated-orcid":false,"given":"Tomoaki","family":"Ida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3528-5695","authenticated-orcid":false,"given":"Kohei","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Tamachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-9381","authenticated-orcid":false,"given":"Hiroshi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ero.2025.05.002_bib0001","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/jof8111167","article-title":"The pathogenesis and diagnosis of Pneumocystis jiroveci pneumonia","volume":"8","author":"Apostolopoulou","year":"2022","journal-title":"J Fungi (Basel)"},{"issue":"5","key":"10.1016\/j.ero.2025.05.002_bib0002","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/ijerph19052768","article-title":"Trends in the epidemiology and outcomes of Pneumocystis pneumonia among human immunodeficiency virus (HIV) hospitalizations","volume":"19","author":"Elango","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"10.1016\/j.ero.2025.05.002_bib0003","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3201\/eid1903.121151","article-title":"Increasing Pneumocystis pneumonia, England, UK, 2000-2010","volume":"19","author":"Maini","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ero.2025.05.002_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2016.03.018","article-title":"Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients","volume":"46","author":"Bienvenu","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.ero.2025.05.002_bib0005","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1378\/chest.118.3.704","article-title":"Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states","volume":"118","author":"Mansharamani","year":"2000","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.ero.2025.05.002_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139144","article-title":"Pneumocystis pneumonia in patients with autoimmune diseases: a retrospective study focused on clinical characteristics and prognostic factors related to death","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ero.2025.05.002_bib0007","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0163-4453(03)00038-0","article-title":"Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study","volume":"47","author":"Roblot","year":"2003","journal-title":"J Infect"},{"issue":"3","key":"10.1016\/j.ero.2025.05.002_bib0008","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jcrc.2013.12.005","article-title":"Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients","volume":"29","author":"Ko","year":"2014","journal-title":"J Crit Care"},{"issue":"3","key":"10.1016\/j.ero.2025.05.002_bib0009","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/00365548.2013.865142","article-title":"Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment","volume":"46","author":"Roblot","year":"2014","journal-title":"Scand J Infect Dis"},{"issue":"2","key":"10.1016\/j.ero.2025.05.002_bib0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis against Pneumocystis jirovecii Pneumonia in adults","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ero.2025.05.002_bib0011","first-page":"47","article-title":"Incidence of Pneumocystis jirovecii pneumonia and prophylaxis-associated adverse events among patients with systemic lupus erythematosus","volume":"52","author":"Jiang","year":"2025","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ero.2025.05.002_bib0012","article-title":"An open-label, randomized controlled trial of sulfamethoxazole-trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up","volume":"4","author":"Utsunomiya","year":"2020","journal-title":"Rheumatol Adv Pract"},{"issue":"5","key":"10.1016\/j.ero.2025.05.002_bib0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jiac.2019.01.005","article-title":"Efficacies of atovaquone, pentamidine, and trimethoprim\/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases","volume":"25","author":"Kitazawa","year":"2019","journal-title":"J Infect Chemother"},{"issue":"8","key":"10.1016\/j.ero.2025.05.002_bib0014","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00296-021-04945-w","article-title":"Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids","volume":"42","author":"Jinno","year":"2022","journal-title":"Rheumatol Int"},{"issue":"3","key":"10.1016\/j.ero.2025.05.002_bib0015","doi-asserted-by":"crossref","first-page":"E184","DOI":"10.1111\/j.1399-0012.2012.01624.x","article-title":"Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation","volume":"26","author":"Gabardi","year":"2012","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.ero.2025.05.002_bib0016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/314893","article-title":"Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides","volume":"180","author":"Chan","year":"1999","journal-title":"J Infect Dis"},{"issue":"26","key":"10.1016\/j.ero.2025.05.002_bib0017","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJM199812243392604","article-title":"Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group","volume":"339","author":"El-Sadr","year":"1998","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ero.2025.05.002_bib0018","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/archinte.162.8.921","article-title":"Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines","volume":"162","author":"Goldie","year":"2002","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.ero.2025.05.002_bib0019","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","article-title":"Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"100400","key":"10.1016\/j.ero.2025.05.002_bib0020","article-title":"Evolving epidemiology of Pneumocystis pneumonia: findings from a longitudinal population-based study and a retrospective multi-center study in Germany","volume":"18","author":"Kolbrink","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"10.1016\/j.ero.2025.05.002_bib0021","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1053\/jlts.2001.26433","article-title":"Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study","volume":"7","author":"Meyers","year":"2001","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.ero.2025.05.002_bib0022","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5414\/CP204368","article-title":"Prevention of Pneumocystis pneumonia in patients with hematological diseases: efficacy of low-dose atovaquone","volume":"61","author":"Sugi","year":"2023","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ero.2025.05.002_bib0023","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.jaad.2018.12.052","article-title":"Incidence of Pneumocystosis among patients exposed to immunosuppression","volume":"80","author":"Rekhtman","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ero.2025.05.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214324","article-title":"Prognostic factors of Pneumocystis pneumonia in patients with systemic autoimmune diseases","volume":"14","author":"Kageyama","year":"2019","journal-title":"PLoS One"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708125000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:53:26Z","timestamp":1778162006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708125000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S3050708125000308"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2025.05.002","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose atovaquone for prophylaxis of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases: an open-label, multicentre, single-arm, phase II trial","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}